Clinical Trial

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Study acronym: A166
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-05.
Trial Details
NCT Number NCT06968585
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions HER2-positive Breast Cancer
Enrollment 365 participants
Start Date 2023-07-18
Primary Completion 2026-11-30 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08